Opinion|Videos|August 6, 2024
Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments
Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- A significant percentage (30%-50%) of patients are still symptomatic with chronic spontaneous urticaria while on certain recommended doses. What do you believe accounts for this high number of patients who are not responding adequately?
- Patients have to come in for first 3 doses because this a biologic. Is this preferred? Is there a burden on these patients?
- Said prescription targets the IgE pathway, but a significant percentage of patients have IgG antibodies as part of their disease pathophysiology. What do you do in your patients who do not respond to this prescription?
- Why is it imperative to develop new treatments that target the IgG pathway?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial
2
OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows
3
FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success
4
After Wild Ride, FDA Grants Accelerated Approval for Replimune’s RP1 Plus Nivolumab in Advanced Melanoma
5